<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9456">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05697406</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00101177</org_study_id>
    <nct_id>NCT05697406</nct_id>
  </id_info>
  <brief_title>HP Pyruvate MRI in Cancers</brief_title>
  <acronym>HC-MRI</acronym>
  <official_title>Hyperpolarized 13-C Pyruvate MRI Surveillance of Multiple Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many human diseases are characterized by their ability to alter existing metabolic pathways&#xD;
      and interrupt cellular processes. Cancer exploits the Warburg effect and utilizes greater&#xD;
      glucose than normal cells and within this process uses anaerobic respiration, leading to&#xD;
      increased conversion of pyruvate to lactate. This can be exploited by hyperpolarized imaging.&#xD;
      Hyperpolarized 13C MRI imaging is an approach that utilizes a stable isotope of Carbon (13C)&#xD;
      linked to pyruvate. MRI spectroscopy is used in conjunction with hyperpolarized 13C pyruvate&#xD;
      in order to temporally detect pyruvate and its conversion to lactate in-vivo, in order to&#xD;
      visualize downstream metabolic (glycolytic) activity secondary to the Warburg effect, which&#xD;
      should be useful in detecting and characterizing tumors of various types. Hyperpolarized 13C&#xD;
      pyruvate MR imaging has not been tested in most cancers. In this preliminary survey, we will&#xD;
      test the hypothesis that hyperpolarized 13C pyruvate MR imaging can be used to image various&#xD;
      cancers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Most cancers exhibit the Warburg effect, which involves synthesis of lactate via glycolytic&#xD;
      pathways. The present method of using 18F-FDG to image metabolic events only evaluates early&#xD;
      glycolysis and does not investigate late glycolytic effects which can be examined by 13C&#xD;
      pyruvate. The ability to detect cancer using 13C pyruvate has been shown using ovarian cancer&#xD;
      models and in the prostate in humans, however its utility in other tumors needs&#xD;
      clarification. Because cancers of various types affect metabolic pathways, it is necessary to&#xD;
      improve imaging techniques to better investigate downstream metabolism. Many studies have&#xD;
      shown that there are higher lactate levels in cancer tissue and higher levels of glycolysis.&#xD;
      13C pyruvate imaging takes advantage of these pathways by imaging the tumors while undergoing&#xD;
      pyruvate to lactate conversion . From this modality, a three dimensional visualization of the&#xD;
      tumor and metabolic products created by the pyruvate can be investigated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 30, 2023</start_date>
  <completion_date type="Anticipated">February 1, 2028</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2026</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Participants will be evaluated pre and post hyperpolarized 13-C pyruvate injection for change in pyruvate signal compared to background.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pyruvate to Lactate Conversion</measure>
    <time_frame>18-36 months</time_frame>
    <description>Imaging Quality, KpL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SNR</measure>
    <time_frame>12-42 months</time_frame>
    <description>Signal to Noise Ratio, dB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CNR</measure>
    <time_frame>12-42 months</time_frame>
    <description>Contrast to Noise</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Image</condition>
  <condition>Warburg Effect</condition>
  <condition>Tumors</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive an injection of 250 mM of hyperpolarized 13-C pyruvate intravenously after standard of care imaging sequences are performed. Then participants will undergo HP-MR imaging.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperpolarized 13C-Pyruvate</intervention_name>
    <description>Imaging tumors pre and post administration of hyperpolarized 13-C pyruvate injection.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Clinical tumor diagnosis&#xD;
&#xD;
        Patients with pre-existing MR imaging appointments&#xD;
&#xD;
        Must be able to undergo MR&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        No tumor diagnosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>88 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Nikita Rednam, BA</last_name>
      <phone>862-596-1018</phone>
      <email>nrednam@som.umaryland.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Albers MJ, Bok R, Chen AP, Cunningham CH, Zierhut ML, Zhang VY, Kohler SJ, Tropp J, Hurd RE, Yen YF, Nelson SJ, Vigneron DB, Kurhanewicz J. Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res. 2008 Oct 15;68(20):8607-15. doi: 10.1158/0008-5472.CAN-08-0749.</citation>
    <PMID>18922937</PMID>
  </reference>
  <reference>
    <citation>Ravoori MK, Singh SP, Lee J, Bankson JA, Kundra V. In Vivo Assessment of Ovarian Tumor Response to Tyrosine Kinase Inhibitor Pazopanib by Using Hyperpolarized 13C-Pyruvate MR Spectroscopy and 18F-FDG PET/CT Imaging in a Mouse Model. Radiology. 2017 Dec;285(3):830-838. doi: 10.1148/radiol.2017161772. Epub 2017 Jul 13.</citation>
    <PMID>28707963</PMID>
  </reference>
  <reference>
    <citation>Wang ZJ, Ohliger MA, Larson PEZ, Gordon JW, Bok RA, Slater J, Villanueva-Meyer JE, Hess CP, Kurhanewicz J, Vigneron DB. Hyperpolarized 13C MRI: State of the Art and Future Directions. Radiology. 2019 May;291(2):273-284. doi: 10.1148/radiol.2019182391. Epub 2019 Mar 5.</citation>
    <PMID>30835184</PMID>
  </reference>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>January 6, 2023</study_first_submitted>
  <study_first_submitted_qc>January 20, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2023</study_first_posted>
  <last_update_submitted>April 14, 2023</last_update_submitted>
  <last_update_submitted_qc>April 14, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Vikas Kundra</investigator_full_name>
    <investigator_title>Chief of Oncologic Imaging</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

